Exhibit
      10.8

    VioQuest
      Pharmaceuticals, Inc.

    


    February
      15, 2006

    


    Pamela
      Jo
      Harris, M.D., F.A.C.P.

    150
      East
      44th
      Street,
      Apt. 8B

    New
      York,
      NY 10017

    


    Dear
      Dr.
      Harris:

    


    On
      behalf
      of VioQuest Pharmaceuticals, Inc. (the “Company”), I am pleased to extend an
      offer of employment to you in the position of Chief Medical
      Officer.

    


    This
      letter (the “Letter”) shall confirm our understanding as to the terms of your
      employment with the Company.

    


    
      	
            	1.	
              This
                letter is being provided to you as an offer to begin work on March
                15,
                2006 (“Effective Date”) as an employee of the Company and receive an
                annual base salary equal to $250,000, payable on a semi-monthly basis.
                You
                will be eligible for a target bonus of 20% of your base salary based
                on
                personal performance, and an additional 10% based on Company performance.
                For the fiscal year 2006, you will be guaranteed a minimum of 50%
                of your
                annual target bonus of 20%.

            


    

    


    
      	
            	2.	
              You
                shall be entitled to receive stock options to purchase 200,000 shares
                of
                the Company’s Common Stock at a per share price equal to the greater of
                (a) $.75 or (b) 105% of the closing bid price of the Company’s Common
                Stock on the OTC Bulletin Board on the Effective Date (the “Standard
                Options”) (subject to adjustment for splits and/or other capital
                restructuring), such Options to vest as follows:
                

            


    

    


    
      	
            	(a)	
              66,666
                of the Standard Options will vest on the date that is one year from
                the
                Effective Date;

            


    

    
      	
            	(b)	
              66,667
                of the Standard Options will vest on the date that is two years from
                the
                Effective Date; 

            


    

    
      	
            	(c)	
              66,667
                of the Standard Options will vest on the date that is three years
                from the
                Effective Date; 

            


    

    


    You
      shall
      be entitled to receive stock options to purchase an additional 200,000 shares
      (“Performance Based Stock Options,” and together with the Standard Options, the
“Options”) of the Company’s Common Stock at a per share price equal to 105% of
      the closing bid price of the Company’s Common Stock on the OTC Bulletin Board,
      on the Effective Date (subject to adjustment for splits and/or other capital
      restructuring), such Options to vest as follows:

    


    
      	
            	(a)	
              66,666
                of the Performance Based Stock Options shall vest over three years
                beginning on September 30, 2006, as the target date of the successful
                completion of patient enrollment in the final cycle for the Phase
                I
                VQD-001 (SSG trial); 

            


    

    
      	
            	(b)	
              66,667
                of the Performance Based Stock Options shall vest over three years
                beginning on September 30, 2006, as the target date of the successful
                completion of patient enrollment in the final cycle for the Phase
                I
                VQD-002 (Akt Trial) by September 30,
                2006;

            


    

    
      	
            	(c)	
              66,667
                of the Performance Based Stock Options shall vest over three years
                beginning on November 30, 2006, as the target date of the successful
                completion of patient enrollment in the final cycle for the Phase
                I for
                VQD-002 (Leukemia Trial);

            


    

    


    The
      above
      Performance Based Stock Option’s entitlement and milestone schedule will be
      predicated one month from the effective start date with the Company’s CEO to
      assess each of the trials’ viability and forecasted timelines. 

     

    
      VioQuest
        Pharmaceuticals, Inc.

      Princeton
        Corporate Plaza, Suite E

      7
        Deer Park Drive, Monmouth Junction, NJ 08852

      Telephone:
        +1 732 274 0399 Fax: +1 732 274 0402 

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    


    All
      terms
      of the Options will be issued pursuant to the Company’s 2003 Stock Option Plan
      (the “2003 Plan”). Options will only vest if you are an employee of the Company
      on the applicable vesting date. Upon the termination of your employment with
      the
      Company, the unvested portions of all options will be deemed
      expired.

    


    Notwithstanding
      the foregoing vesting terms relating to the In the event the Company completes
      a
      transaction in which it sells the assets or stock of VioQuest Pharmaceuticals,
      Inc., resulting in a Change of Control (as defined in the 2003 Plan), then
      the
      vesting terms of the stock options shall accelerate and all shares of common
      stock shall become immediately exercisable. The specific terms of the Options
      will be governed by a separate stock option agreement(s).

    


    
      	
            	4.	
              You
                shall be reimbursed for all of your pre-approved out-of-pocket expenses
                incurred in connections with the Company’s
                business.

            


    

    


    
      	
            	5.	
              You
                will be entitled to participate in the full benefits package which
                includes medical, dental, life and travel insurances, as well as
                the
                Company’s 401(k) program pursuant to the group policy of the Company.
                

            


    

    


    
      	
            	6.	
              Your
                employment with the Company will be for an indefinite term and nothing
                in
                this Letter modifies your at-will employment relationship with the
                Company. However, if the Company terminates your employment without
                cause,
                you will be eligible for severance pay equal to six months of your
                then
                annualized base salary. Severance will be payable in semi-monthly
                installments over such six-month period, in accordance with the Company’s
                normal payroll practices in effect at such time. Severance will only
                be
                paid, however, if you execute a separate severance and release agreement
                that the Company would prepare. You may terminate your employment
                with the
                Company, for any reason, upon 60 days
                notice.

            


    

    


    
      	
            	7.	
              You
                shall receive 15 business days as vacation
                days.

            


    

    


    
      	
            	8.	
              The
                Company will provide you with a housing allowance reimbursement up
                to
                $10,000 for the first six months upon joining the Company. After
                the six
                months have expired, or during that time, the Company will provide
                housing
                relocation assistance up to $10,000 net of taxes. The housing allowance
                for $10,000 and housing relocation for $10,000 by the Company will
                be
                reimbursed to you once an approved expense report with accompanying
                receipts has been submitted by you.

            


    

    


    
      	
            	9.	
              Your
                title at the Company shall be Chief Medical Officer, and you shall
                be
                principally responsible for successfully designing, implementing,
                and
                reporting the Company’s clinical trials, and to ensure the clinical trials
                meet the highest standards of excellence for ethics, scientific merit
                and
                regulatory compliance, as well as satisfy corporate goals and meet
                timeliness for approval. You will report to the President and
                CEO.

            


    

    


    
      	
            	10.	
              You
                represent to the Company that your employment with the Company will
                not
                constitute a breach or other violation of any agreement or contract
                under
                which you are bound or any other obligation that you owe to any third
                party. You further represent that no approvals or consents are required
                in
                order for you to be employed by the Company as contemplated by this
                letter.

            


    

     

    
      	
            	11.	
              Your
                employment with the Company will also be subject to our established
                policies and procedures, including the Company’s code of ethics and
                employee manual. In particular, you acknowledge the provisions of
                the
                employee manual set forth under the caption “Confidentiality and
                Intellectual Property Assignment Agreement” and agree that you will be
                bound by the terms of such section (as well as the other provisions
                of the
                employee manual). 

            


    

     

    
      	
            	12.	
              You
                agree during your term of employment with the Company and for twelve
                months following the end of your employment, you will not solicit
                the
                business of, interfere with, disrupt, or attempt to disrupt, the
                Company's
                business relationship with, any of its clients or investors, or solicit
                any of the Company's employees. 

            


    

     

    
      	
            	13.	
              You
                further agree during your term of employment with the Company and
                for six
                months following the end of your employment, you will not engage
                in any
                business activity without the Company’s consent, in the areas of
                phosphorylated Akt, protein tyrosine phosphatases, HCV and HBV, in
                addition to other proprietary information developed by the Company
                during
                your term of employment. 

            


    

    
       

      
        VioQuest
          Pharmaceuticals, Inc.

        Princeton
          Corporate Plaza, Suite E

        7
          Deer Park Drive, Monmouth Junction, NJ 08852

        Telephone:
          +1 732 274 0399 Fax: +1 732 274 0402 

         

      

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

       

    

    
      
        
          	
                	
                  14.

                	
                  The
                    Company will reimburse you for, industry related journals, books
                    and
                    subscriptions, in an amount not to exceed $1,500.
                    

                


        

      

    

    


    
      
        	
              	15.	
                The
                  Company will reimburse you for one active medical license once
                  approved by
                  the Company’s CEO.

              


      

    

    


    
      
        	
              	16.	
                The
                  Company will grant you one week of continuing medical education
                  (CME)
                  classes or other CME activities/year. The cost of these classes,
                  travel to
                  and from these classes and reasonable accommodations will be reimbursed
                  by
                  the Company once approved by the CEO, in addition to providing
                  an expense
                  report and accompanying
                  receipts.

              


      

    

    


    
      
        	
              	17.	
                This
                  offer letter is contingent upon the satisfactory completion of
                  your
                  references and background
                  checks.

              


      

    

    


    
      
        	
              	18.	
                This
                  offer letter is contingent upon the approval of the Compensation
                  Committee
                  of the Board of Directors.

              


      

    

    


    A
      timely
      response on your behalf would be appreciated by the Company. 

    


    This
      offer for employment is valid until February 10, 2006. If the Company does
      not
      receive a response by you as of this date, the offer will expire.

    


    If
      you
      find the foregoing arrangement acceptable and believe that the foregoing
      accurately summarizes our understanding, please kindly so indicate by executing
      and dating the attached copy of this letter in the space provided and returning
      a copy to me.

     

    
      	 	 	 
	 	Very
              truly yours,
	 	 
	 	VioQuest
              Pharmaceuticals, Inc.
	 	 
	 	 
	 	/s/ Daniel Greenleaf
	 	
              
Daniel
              Greenleaf
	 	President and
              CEO


    

     

       

    READ
      AND
      ACCEPTED:

    


    


    /s/
      Pamela Jo
      Harris                          


    Pamela
      Jo
      Harris, M.D., F.A.C.P.

    
       

      
        VioQuest
          Pharmaceuticals, Inc.

        Princeton
          Corporate Plaza, Suite E

        7
          Deer Park Drive, Monmouth Junction, NJ 08852

        Telephone:
          +1 732 274 0399 Fax: +1 732 274 0402 

         

      

    

    
      
        
        

      

      
        3